BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021:ciab549. [PMID: 34164674 DOI: 10.1093/cid/ciab549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Carlson TJ, Gonzales-Luna AJ, Garey KW. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med 2022;43:28-38. [PMID: 35172356 DOI: 10.1055/s-0041-1740973] [Reference Citation Analysis]
2 Blumberg EA, Collins G, Young JH, Nguyen MH, Michonneau D, Temesgen Z, Origȕen J, Barcan L, Obeid KM, Belloso WH, Gras J, Corbelli GM, Neaton JD, Lundgren J, Snydman DR, Molina JM; INSIGHT Clostridioides difficile Study Group. Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. Transpl Infect Dis 2021;:e13770. [PMID: 34821423 DOI: 10.1111/tid.13770] [Reference Citation Analysis]
3 Choi MH, Kim D, Jeong SH, Lee HM, Kim H. Risk Factors of Severe Clostridioides difficile Infection; Sequential Organ Failure Assessment Score, Antibiotics, and Ribotypes. Front Microbiol 2022;13:900681. [DOI: 10.3389/fmicb.2022.900681] [Reference Citation Analysis]
4 Piotrowski M, Wultańska D, Pituch H. Effect of prebiotics on Bacteroides sp. adhesion and biofilm formation and synbiotic effect on Clostridioides difficile. Future Microbiol 2022. [PMID: 35172601 DOI: 10.2217/fmb-2021-0206] [Reference Citation Analysis]
5 Orenstein R, Dubberke ER, Khanna S, Lee CH, Yoho D, Johnson S, Hecht G, Dupont HL, Gerding DN, Blount KF, Mische S, Harvey A. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07256-y] [Reference Citation Analysis]
6 Kubeček O, Paterová P, Novosadová M. Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. Life (Basel) 2021;11:1387. [PMID: 34947918 DOI: 10.3390/life11121387] [Reference Citation Analysis]
7 Wingen-Heimann SM, van Prehn J, Kuijper EJ, Vehreschild MJGT. The need for a holistic view on management of Clostridioides difficile infection. Clin Microbiol Infect 2021:S1198-743X(21)00406-7. [PMID: 34311078 DOI: 10.1016/j.cmi.2021.07.014] [Reference Citation Analysis]
8 Hammeken LH, Baunwall SMD, Dahlerup JF, Hvas CL, Ehlers LH. Health-related quality of life in patients with recurrent Clostridioides difficile infections. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078441] [Reference Citation Analysis]
9 Buehrle D, Clancy CJ. Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection. Clin Infect Dis 2021:ciab898. [PMID: 34626478 DOI: 10.1093/cid/ciab898] [Reference Citation Analysis]
10 Singh SB, Miesel L, Kramer S, Xu L, Li F, Lan J, Lipari P, Polishook JD, Liu G, Liang L, Flattery AM. Nocathiacin, Thiazomycin, and Polar Analogs Are Highly Effective Agents against Toxigenic Clostridioides difficile. J Nat Prod 2022. [PMID: 35380836 DOI: 10.1021/acs.jnatprod.2c00093] [Reference Citation Analysis]
11 Amjad W, Qureshi W, Malik A, Singh R, Jafri SM. The outcomes of Clostridioides difficile infection in inpatient liver transplant population. Transpl Infect Dis 2021;:e13750. [PMID: 34695277 DOI: 10.1111/tid.13750] [Reference Citation Analysis]
12 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
13 Kerr PS, Nguyen NT, Martinez A, Srinivasan A, Kosarek CD, Sreshta JN. Robotic pyelolithotomy in a solitary pelvic kidney complicated with fulminant Clostridium difficile: a case report. J Med Case Rep 2022;16:126. [PMID: 35331313 DOI: 10.1186/s13256-022-03345-3] [Reference Citation Analysis]
14 Correa-Martínez CL, Hagemeier NCJ, Froböse NJ, Kampmeier S. Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci. Pharmaceuticals (Basel) 2021;14:1066. [PMID: 34832848 DOI: 10.3390/ph14111066] [Reference Citation Analysis]
15 Hu C, Beyda ND, Garey KW. A Vancomycin HPLC Assay for Use in Gut Microbiome Research. Microbiol Spectr 2022;:e0168821. [PMID: 35536037 DOI: 10.1128/spectrum.01688-21] [Reference Citation Analysis]
16 Askar SF, Kenney RM, Tariq Z, Conner R, Williams J, Ramesh M, Alangaden GJ. Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients. J Pharm Pract 2022;:8971900221074929. [PMID: 35090351 DOI: 10.1177/08971900221074929] [Reference Citation Analysis]